What's new?

Appointment of Non-Executive Director and changes to Board committees   Alderley Park, 5 August 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce, following the successful completion of the loan note fundraising and receipt of funds, the a...

Redx signs out licensing agreement with AstraZeneca   AstraZeneca granted exclusive global licence for the development and commercialisation of RXC006, a porcupine inhibitor, for fibrotic diseases Redx will receive up to $17 million in early payments between deal signature and the successful commencement of first c...

Seasoned Medical Executive to Commercialize CorVent's RESPOND-19™ Ventilator

Serial entrepreneur brings exceptional experience from a range of leadership roles   Italy, Milan, 30 July 2020: Genespire, a gene therapy company developing transformative therapies for genetic diseases, today announces the appointment of Jörn Aldag as Chairman of the Board.

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™ the world’s first enzymatic DNA printer. July 29, 2020 03:00 AM Eastern Daylight Time PARIS & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--DNA Script today announced a $50 million extension to its Series B financing, bringing the to...

Financing co-led by seed investor Sofinnova Partners and incoming investor AbbVie, with additional investment from JDRF T1D Fund and several Italian investors   Largest international VC-backed Series A financing round for biotech in Italy to date and first ever venture investment in an Italian company by AbbVie   F...

Inotrem’s clinical study on Covid-19 was selected by the French government to be part of its €78 M action plan aimed at reinforcing the countries’ research capabilities for therapeutic solutions.   Pre-clinical studies have demonstrated nangibotide’s capacity to restore an appropriate immune response by targeting t...

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced the strengthening of the Company’s Scientific Advisory Board (...

Clichy, France, July 21st, 2020 – CorWave is one of the 44 companies selected among 1,800+ applicants by the European public program EIC Accelerator. CorWave will receive a €2.5 million grant from the European Innovation Council (EIC) to develop its innovative Left Ventricular Assist Device (LVAD). 

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensat...